Complement 1, a health tech company transforming cancer care through personalized lifestyle medicine, announced a $16 million oversubscribed seed funding round led by Owl Ventures and Blume Ventures. It also includes participation from healthcare-focused angel investors, reflecting widespread investor confidence in the company’s impact and market potential.
The company emerged from stealth to launch the first tech-enabled and clinically validated lifestyle modification platform for cancer patients and high-risk individuals, delivering personalized, daily guidance and education through one-on-one dedicated CoActive Coaches.
Complement 1 works as a lifestyle modification platform with physical activity, nutrition, and somatic practices, customized for cancer type and stage, delivered by dedicated CoActive 1:1 Coaches. And the platform’s evidence-backed, medically validated rule engine tailors the program to each individual’s cancer type, treatment stage, side-effect profile, and personal preferences, utilizing guidelines developed by leading oncologists and in partnership with the American Institute for Cancer Research. The result is a highly customized, holistic care pathway that patients can realistically stick with.
Value proposition: For the nearly 1 in 2 Americans who will be diagnosed with cancer in their lifetime, integrating healthy lifestyle changes into cancer care and prevention can be transformative. And decades of research have shown that improvements in diet, physical activity, stress management and other behaviors can significantly reduce cancer recurrence and mortality—by 35% and 37%, respectively—and boost patients’ quality of life.
The company’s platform is among the first built on multiple meta studies demonstrating lifestyle modifications’ significant impact on cancer-related health outcomes, including patient quality of life, cancer recurrence, and mortality. As validated by clinical trials, Complement 1 members report 37% fewer treatment side effects, 18% less pain, and 27% better sleep while achieving an over 90% adherence rate among users. Meanwhile, the platform helps health plans, employers, and providers reduce costs for cancer patients by up to 30%.
**What the funding will be used for: **With the new funding, Complement 1 plans to scale up its coaching infrastructure and operations across the US, advance its AI-driven personalization engine, and partner with cancer centers, health plans, and employers to bring the program to their cancer patients, high-risk individuals, and survivors. And the company will also invest in product development to enhance the digital user experience for patients and coaches.
KEY QUOTES:
“Lifestyle change is one of the most powerful yet underused tools in cancer care. Every oncologist will tell you patients need more support incorporating clinically recommended physical activity, nutrition and mind-body practices. We’ve cracked the code on daily engagement with personalized, compassionate coaching—helping patients make meaningful, lasting improvements during and beyond treatment.”
Karan Bajaj, CEO and Co-Founder of Complement 1
“I’ve seen targeted lifestyle changes transform outcomes—from better energy to reducing recurrence risk. The challenge has always been getting patients to implement those changes and stick with them. Complement 1’s platform provides the intensive support patients need to make sustainable lifestyle shifts, with adherence rates I’ve never seen before in this field.”
Dr. Neil M. Iyengar, MD, a leading exercise-oncology researcher and board member of Complement 1
“Most coaching models rely on a weekly check-in. We meet patients every single day. That daily presence—powered by our CoActive Coaching method—is what creates the trust, accountability, and behavior change that drive our clinical results. This funding allows us to scale that impact by investing further in our AI systems to ensure consistency, personalization, and quality at scale. It’s a hybrid approach: high-tech infrastructure matched with high-touch delivery—designed specifically for the complexity of cancer care.”
Trupti Mukker, Co-founder and COO of Complement 1
“With rising cancer incidence rates, Complement 1 is creating a revolutionary new model to improve global cancer outcomes. We were impressed by the team’s ability to combine high-tech personalization and education with high-touch CoActive Coaching focused on physical activity, somatic and nutrition human guidance to solve a critical gap in oncology. We’re thrilled to support Complement 1 in bringing this much-needed solution to patients and health systems.”
Amit A. Patel, Managing Director at Owl Ventures
